Hyloris PharmaceuticalsFRA:52U -6.85%68 PB Ratio is 4.60 as of Jul. 08, 2026, which is 25% below its 10-year median of 6.10. GuruFocus rates FRA:52U with a GF Score™ of 68/100 and a GF Value™ of €8.32 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,225 Biotechnology companies, Hyloris Pharmaceuticals ranks worse than 67.84% on this metric.
Hyloris Pharmaceuticals SA stock PB Ratio (=4.78) is close to 1-year low of 4.62.
The historical rank and industry rank for Hyloris Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:52U'
s PB Ratio Range Over the Past 10 Years
Min: 2.78 Med: 6.1 Max: 10.78
Current: 5.14
During the past 10 years, Hyloris Pharmaceuticals's highest PB Ratio was 10.78. The lowest was 2.78. And the median was 6.10.
FRA:52U's PB Ratio is ranked worse than 67.84% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs FRA:52U: 5.14
During the past 12 months, Hyloris Pharmaceuticals's average Book Value Per Share Growth Rate was -17.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -21.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.60% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Hyloris Pharmaceuticals was -12.50% per year. The lowest was -67.00% per year. And the median was -18.15% per year.
Back to Basics: PB Ratio
Hyloris Pharmaceuticals (FRA:52U) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hyloris Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hyloris Pharmaceuticals (FRA:52U) has a PB Ratio of 4.60 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hyloris Pharmaceuticals and its competitors. This is 25% below median its historical median of 6.10. Over the past decade, Hyloris Pharmaceuticals' PB Ratio has ranged from 2.78 to 10.78. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #831 out of 1225 companies in the Biotechnology industry, placing it in the top 67.8%.
Is Hyloris Pharmaceuticals' PB Ratio too high?
Hyloris Pharmaceuticals' current PB Ratio of 4.60 is 25% below median its 10-year median of 6.10. Over the past 10 years, this metric has ranged from a low of 2.78 to a high of 10.78. The Biotechnology industry median PB Ratio is 2.92. Hyloris Pharmaceuticals' value of 4.60 is 57.5% above this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #831 out of 1225 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #831 out of 1225 companies for PB Ratio. This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.92. Hyloris Pharmaceuticals' value of 4.60 is 57.5% above this benchmark. Historically, Hyloris Pharmaceuticals' own PB Ratio has ranged from 2.78 to 10.78 over the past decade. While the company's 10-year median is 6.10 vs. the industry median of 2.92, Hyloris Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current PB Ratio of 4.60 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current PB Ratio is 4.60, which is 25% below median its own 10-year median of 6.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (FRA:52U) is currently considered Possible Value Trap. The stock's GF Value™ is €8.32, compared to a current price of €4.35 — trading 47.7% below its estimated fair value. The current PB Ratio is 4.60, which is 25% below median its 10-year median of 6.10 and 57.5% above the Biotechnology industry median of 2.92. Hyloris Pharmaceuticals' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hyloris Pharmaceuticals (FRA:52U), the current PB Ratio is 4.60 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (FRA:52U) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.35 is trading 47.7% below its estimated GF Value™ of €8.32.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:52U:
PB Ratio: 4.60 (25% below median its 10-year median of 6.10)
GF Value™: €8.32 vs. price of €4.35 (47.7% below fair value)
Industry Position: 57.5% above the Biotechnology median (#831 of 1225)
No single metric tells the full story. See the FRA:52U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
68GF Score
Get the complete analysis for FRA:52U
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:52U has been successfully added to your 
